Identification of New Markers in the Hypereosinophilic Syndrome (SHE)

University Hospital, Lille

Status: Completed

Conditions: Hypereosinophilic Syndrome

Treatments: Biological: biologie sample

Study type: Interventional

Funder types: Other

Identifiers

NCT01713504

2008_29

2009-A00314-53 (Other Identifier)

Details and patient eligibility

About

The purpose is to characterize new hypereosinophilic syndrome biomarkers more informative and more accessible compared to those that we have already thanks to a proteomic approach. This will help the investigators to diagnose the this disease.

Enrollment: 41 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• dated and signed informed consent
• virale serology negative or negative result less than 6 months
• virale serology negative for HBV or vaccinated patient
• insured
• virale serology negative or negative result less than 6 months
• negative pregnancy test or female menopause for at least 1 year

Exclusion criteria

• subject enable adult, under guardianship or under protective measures of justice
• Refusal or inability to give informed consent
• The hypereosinophilic syndrome explained origin other than than atopy, bullous pemphigoid, the Churg-Strauss syndrome and DRESS

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

41 participants in 3 patient groups

Hypereosinophilic syndrome unexplained

Experimental group

Treatment:

Biological: biologie sample

Hypereosinophilic syndrome explained

Active Comparator group

Treatment:

Biological: biologie sample

Normal rate of eosinophilic

Sham Comparator group

Treatment:

Biological: biologie sample